Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells

European Journal of Pharmacology

Volumn 475, Issue 1-3, 2003, Pages 139-147

  Sonoki, Kazuo ^a   Iwase, Masanori ^a   Iino, Kenzo ^a   Ichikawa, Kojiro ^a   Yoshinari, Mototaka ^a   Ohdo, Shigehiro ^b   Higuchi, Shun ^b   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Diabetes mellitus; Glycoxidized; Human; LDL (low density lipoprotein); MCP 1 (monocyte chemoattractant protein 1); NF B (nuclear factor B); Umbilical vein endothelial cell

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; DILAZEP; DRUG METABOLITE; FENOFIBRATE; FENOFIBRIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GLYCATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIPID PEROXIDATION; MEASUREMENT; OXIDATION; PRIORITY JOURNAL; RNA ANALYSIS;

EID: 0042381862     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02109-5     Document Type: Article

References (49)

1. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Natoli E., Rollins B.J., Milos P.M. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1999;1518-1525.
2. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:1959;911-917.
3. Bouma M.G., Van Den Wildenberg F.J.M., Buurman W.A. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am. J. Physiol. 270:1996;C522-C529.
4. Bowie A., Owens D., Collins P., Johnson A., Tomkin G.H. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis. 102:1993;63-67.
5. Chapman M.J., Guerin M., Bruckert E. Atherogenic, dense low-density lipoproteins; pathophysiology and new therapeutic approaches. Eur. Heart. J. 19(Suppl. A):1998;A24-A30.
6. Chaput E., Maubrou-Sanchez D., Bellamy F.D., Edgar A.D. Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with α-tocopherol. Lipids. 34:1999;497-502.
7. Chen M., Nagase M., Fujita T., Narumiya S., Masaki T., Sawamura T. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGE. Biochem. Biophys. Res. Commun. 287:2001;962-968.
8. Cohen M.P., Lautenslager G., Shea E. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur. J. Clin. Chem. Clin. Biochem. 31:1993;707-713.
9. Collins T. Endothelial nuclear factor-κB and initiation of the atherosclerotic lesion. Lab. Invest. 68:1993;499-508.
10. Cominacini L., Pasini A.F., Garbin U., Davoli A., Tosetti M.L., Campagnola M., Rigoni A., Pastorino A.M., Lo Cascio V., Sawamura T. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J. Biol. Chem. 275:2000;12633-12638.
11. Cushing S.D., Berliner J.A., Valente A.J., Territo M.C., Navab M., Parhami F., Gerrity R., Schwartz C.J., Fogelman A.M. Minimally modified low-density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 87:1990;5134-5138.
12. De Graaf J., Hal-Lemmers H.L.M., Hectors M.P.C., Demarker P.N.M., Hendriks J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11:1991;298-306.
13. Deguchi H., Takeya H., Wada H., Gabazza E.C., Hayashi N., Urano H., Suzuki K. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood. 90:1997;2345-2356.
14. Diabetes atherosclerosis intervention study investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomized study. Lancet. 357:2001;905-910.
15. 2B receptors in angiogenic factor regulation. Circ. Res. 90:2002;531-538.
16. Flohe L., Brigelius-Flohe R., Saliou C., Traber M.G., Packer L. Redox regulation of NF-kappa B activation. Free Radical. Biol. Med. 22:1997;1115-1126.
17. Gillery P., Monboisse J.C., Maquart F.X., Borel J.P. Glycation of proteins as a source of superoxide. Diab. Metab. 14:1988;25-30.
18. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Mol. Cell. 2:1998;275-281.
19. Han X., Gubitosi-Klug R.A., Collins B.J., Gross R.W. Alterations in individual molecular species of human platelet phospholipids during thrombin stimulation: electrospray ionization mass spectrometry-facilitated identification of the boundary conditions for the magnitude and selectivity of thrombin-induced platelet phospholipid hydrolysis. Biochemistry. 35:1996;5822-5832.
20. Hunt J.V., Smith C.C., Wolff S.P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 39:1990;1420-1424.
21. Imanaga Y., Sakata N., Takebayashi S., Matsunaga A., Sakai J., Arakawa K., Nagai R., Horiuchi S., Itabe H., Takano T. In vivo and in vitro evidence for the glycoxidation of low-density lipoprotein in human atherosclerotic plaques. Atherosclerosis. 150:2000;343-355.
22. Inoue I., Shio K., Noji S., Awata T., Katayama S. Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246:1998;370-374.
23. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest. 52:1973;2745-2756.
24. Kaluzny M.A., Duncan L.A., Merritt M.V., Epps D.E. Rapid separation of lipid classes in high yield and purity using bonded phase columns. J. Lipid. Res. 26:1985;135-140.
25. Kawamura M., Heinecke J.W., Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J. Clin. Invest. 94:1994;771-778.
26. Klein R.L., Laimins M., Lopes-Virella M.F. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes. 44:1995;1093-1098.
27. Li C., Ha T., Liu L., Browder W., Kao R.L. Adenosine prevents activation of transcription factor NFκB and enhances activator protein-1 binding activity in ischemic rat heart. Surgery. 127:2000;161-169.
28. Marx N., Sukhova G.K., Collins T., Libby P., Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99:1999;3125-3131.
29. Mustafa S.J. Effect of coronary vasodilator drugs on the uptake and release of adenosine in cardiac cells. Biochem. Pharmacol. 28:1979;2617-2624.
30. Nakamura K., Kojima K., Arai T., Shirai M., Usutani S., Akimoto H., Masaoka H., Nagase M., Yamamoto M. Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats. Eur. J. Clin. Invest. 28:1998;877-883.
31. Nelken N.A., Coughin S.R., Gordon D., Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. 88:1991;1121-1127.
32. Nilsson L., Takemura T., Eriksson P., Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19:1999;1577-1581.
33. Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y., Tanaka T., Miwa S., Katsura Y., Kita T., Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 386:1997;73-77.
34. Schaumloffel E., Prignitz R. Isotope-technical studies on pharmacokinetics and metabolism of dilazep in man. Drug Res. 22:1972;1651-1655.
35. Schreiber E., Matthias P., Muller M.M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17:1989;6419.
36. Shepherd J. The fibrates in clinical practice: focus on micronised fenofibrate. Atherosclerosis. 110:1994;S55-S63. (Suppl.).
37. Sonoki K., Yoshinari M., Iwase M., Iino K., Ichikawa K., Ohdo S., Higuchi S., Iida M. Glycoxidized low-density lipoprotein enhances MCP-1 mRNA expression in HUVEC: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism. 51:2002;1135-1142.
38. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
39. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 393:1998;790-793.
40. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
41. Thornalley P.J. Monosaccharide autoxidation in health and disease. Environ. Health Perspect. 64:1985;297-307.
42. Tooke J.E. Diabetic Angiopathy. 1996;Arnold, London, UK.
43. Tsai E.C., Hirsch I.B., Brunzel J.D., Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 43:1994;1010-1014.
44. Vieira O.V., Laranjinha J.A.N., Madeira V.M.C., Almeida L.M. Rapid isolation of low density lipoproteins in a concentrated fraction free from water-soluble plasma antioxidants. J. Lipid Res. 37:1996;2715-2721.
45. MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J. 16:2002;1584-1594.
46. Xu X., Otsuki M., Saito H., Sumitani S., Yamamoto H., Asanuma N., Kouhara H., Kasayama S. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology. 142:2001;3332-3339.
47. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem. Med. 15:1976;212-216.
48. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., Sarkioja T., Yoshimura T., Leonard E.J., Witztum J.L., Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5252-5256.
49. Zhang Y., Greiger J., Legare D., Lautt W. Dilazep-induced vasodilation is mediated through adenosine receptors. Life Sci. 49:1991;PL129-PL133.